VTRS Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of 2.53% compared to Viatris's net margin of --. Viatris's return on equity of -4.39% beat Perspective Therapeutics's return on equity of --.

Viatris has a consensus price target of --, signalling upside risk potential of 7.34%. On the other hand Perspective Therapeutics has an analysts' consensus of -- which suggests that it could grow by 466.67%. Given that Perspective Therapeutics has higher upside potential than Viatris, analysts believe Perspective Therapeutics is more attractive than Viatris.

Viatris has a beta of 0.964, which suggesting that the stock is 3.557% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 3.83%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays 1052.29% of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Viatris quarterly revenues are $3.8B, which are larger than Perspective Therapeutics quarterly revenues of --. Viatris's net income of $94.8M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Viatris's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 1.00x versus 15.39x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of 2.53% compared to Viatris's net margin of 16.61%. Viatris's return on equity of -4.39% beat Gilead Sciences's return on equity of 0.64%.

Viatris has a consensus price target of --, signalling upside risk potential of 7.34%. On the other hand Gilead Sciences has an analysts' consensus of $98.92 which suggests that it could grow by 6.86%. Given that Viatris has higher upside potential than Gilead Sciences, analysts believe Viatris is more attractive than Gilead Sciences.

Viatris has a beta of 0.964, which suggesting that the stock is 3.557% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.175, suggesting its less volatile than the S&P 500 by 82.499%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 3.83%. Gilead Sciences offers a yield of 3.33% to investors and pays a quarterly dividend of $0.77 per share. Viatris pays 1052.29% of its earnings as a dividend. Gilead Sciences pays out 67.24% of its earnings as a dividend. Gilead Sciences's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Viatris's is not.

Viatris quarterly revenues are $3.8B, which are smaller than Gilead Sciences quarterly revenues of $7.5B. Viatris's net income of $94.8M is lower than Gilead Sciences's net income of $1.3B. Notably, Viatris's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 1,028.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 1.00x versus 4.09x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Lexicon Pharmaceuticals has a net margin of 2.53% compared to Viatris's net margin of -3703.49%. Viatris's return on equity of -4.39% beat Lexicon Pharmaceuticals's return on equity of -115.11%.

Viatris has a consensus price target of --, signalling upside risk potential of 7.34%. On the other hand Lexicon Pharmaceuticals has an analysts' consensus of $3.60 which suggests that it could grow by 403.71%. Given that Lexicon Pharmaceuticals has higher upside potential than Viatris, analysts believe Lexicon Pharmaceuticals is more attractive than Viatris.

Viatris has a beta of 0.964, which suggesting that the stock is 3.557% less volatile than S&P 500. In comparison Lexicon Pharmaceuticals has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.862%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 3.83%. Lexicon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays 1052.29% of its earnings as a dividend. Lexicon Pharmaceuticals pays out -- of its earnings as a dividend.

Viatris quarterly revenues are $3.8B, which are larger than Lexicon Pharmaceuticals quarterly revenues of $1.8M. Viatris's net income of $94.8M is higher than Lexicon Pharmaceuticals's net income of -$64.8M. Notably, Viatris's price-to-earnings ratio is -- while Lexicon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 1.00x versus 39.74x for Lexicon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 2.53% compared to Viatris's net margin of 0.7%. Viatris's return on equity of -4.39% beat Moderna's return on equity of -17.44%.

Viatris has a consensus price target of --, signalling upside risk potential of 7.34%. On the other hand Moderna has an analysts' consensus of $127.09 which suggests that it could grow by 88.34%. Given that Moderna has higher upside potential than Viatris, analysts believe Moderna is more attractive than Viatris.

Viatris has a beta of 0.964, which suggesting that the stock is 3.557% less volatile than S&P 500. In comparison Moderna has a beta of 1.582, suggesting its more volatile than the S&P 500 by 58.238%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 3.83%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays 1052.29% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Viatris quarterly revenues are $3.8B, which are larger than Moderna quarterly revenues of $1.9B. Viatris's net income of $94.8M is higher than Moderna's net income of $13M. Notably, Viatris's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 1.00x versus 3.01x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.